Drug utilization in the era of big data
Big data in healthcare refers to electronic health data sets that are so large and complex that it would be difficult to manage and analyze using traditional software and data management tools and methods. Big data in healthcare is also known as large health care databases which is one of the source...
| Main Author: | |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2018
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/66684/ http://irep.iium.edu.my/66684/1/181008_Suraya_ICPRP.pdf |
| id |
iium-66684 |
|---|---|
| recordtype |
eprints |
| spelling |
iium-666842018-10-16T08:00:10Z http://irep.iium.edu.my/66684/ Drug utilization in the era of big data Zin, Che Suraya RM300 Drugs and their action Big data in healthcare refers to electronic health data sets that are so large and complex that it would be difficult to manage and analyze using traditional software and data management tools and methods. Big data in healthcare is also known as large health care databases which is one of the sources for drug utilization study. It is often used to address research questions on drug use and drug effect such as evaluation of the processes of prescribing, dispensing and consumption of medicines to improve the quality use of medicines in populations. Large healthcare databases, which contain data collected during routinely delivered healthcare to patients, can serve as a valuable resource for generating actionable evidence to assist in medical and healthcare policy decision-making. The sources of large healthcare data include electronic medical records, health insurance claims and patient registries. Data may be collected on drug sales, prescriptions, drug distribution chain, pharmaceutical and medical billing. The scope of the databases may be international, national or local. The databases may be diagnosis-linked or non-diagnosis-linked. Diagnosis-linked data enable drug use to be analyzed according to patient characteristics, therapeutic groups, diseases or conditions and, in the best of cases, clinical outcome. A useful analysis requires an understanding of the sources and organization of the data. Harnessing the power of information contained in large healthcare databases, while paying close attention to their inherent limitations, is critical to generate rigorous evidence-base for medical decision-making and ultimately enhancing patient care. 2018 Conference or Workshop Item NonPeerReviewed application/pdf en http://irep.iium.edu.my/66684/1/181008_Suraya_ICPRP.pdf Zin, Che Suraya (2018) Drug utilization in the era of big data. In: International Conference on Pharmaceutical Research and Practice, 5th-6th October 2018, Yogjakarta, Indonesia. (Unpublished) |
| repository_type |
Digital Repository |
| institution_category |
Local University |
| institution |
International Islamic University Malaysia |
| building |
IIUM Repository |
| collection |
Online Access |
| language |
English |
| topic |
RM300 Drugs and their action |
| spellingShingle |
RM300 Drugs and their action Zin, Che Suraya Drug utilization in the era of big data |
| description |
Big data in healthcare refers to electronic health data sets that are so large and complex that it would be difficult to manage and analyze using traditional software and data management tools and methods. Big data in healthcare is also known as large health care databases which is one of the sources for drug utilization study. It is often used to address research questions on drug use and drug effect such as evaluation of the processes of prescribing, dispensing and consumption of medicines to improve the quality use of medicines in populations.
Large healthcare databases, which contain data collected during routinely delivered healthcare to patients, can serve as a valuable resource for generating actionable evidence to assist in medical and healthcare policy decision-making. The sources of large healthcare data include electronic medical records, health insurance claims and patient registries. Data may be collected on drug sales, prescriptions, drug distribution chain, pharmaceutical and medical billing. The scope of the databases may be international, national or local. The databases may be diagnosis-linked or non-diagnosis-linked. Diagnosis-linked data enable drug use to be analyzed according to patient characteristics, therapeutic groups, diseases or conditions and, in the best of cases, clinical outcome. A useful analysis requires an understanding of the sources and organization of the data.
Harnessing the power of information contained in large healthcare databases, while paying close attention to their inherent limitations, is critical to generate rigorous evidence-base for medical decision-making and ultimately enhancing patient care. |
| format |
Conference or Workshop Item |
| author |
Zin, Che Suraya |
| author_facet |
Zin, Che Suraya |
| author_sort |
Zin, Che Suraya |
| title |
Drug utilization in the era of big data |
| title_short |
Drug utilization in the era of big data |
| title_full |
Drug utilization in the era of big data |
| title_fullStr |
Drug utilization in the era of big data |
| title_full_unstemmed |
Drug utilization in the era of big data |
| title_sort |
drug utilization in the era of big data |
| publishDate |
2018 |
| url |
http://irep.iium.edu.my/66684/ http://irep.iium.edu.my/66684/1/181008_Suraya_ICPRP.pdf |
| first_indexed |
2023-09-18T21:34:42Z |
| last_indexed |
2023-09-18T21:34:42Z |
| _version_ |
1777412742727073792 |